ArticleFrontiers in pediatrics2020
Epigenetic Regulation of Macrophage Marker Expression Profiles in Kawasaki Disease.
Article in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Construction and validation of a diagnostic model for Kawasaki disease based on neutrophil-related genes and analysis of immune infiltration.Translational pediatrics · 2026Article
- Targeting STAT3 pathway attenuates macrophages inflammation and cardiovascular injury in a model of Kawasaki disease.Scientific reports · 2026Article
- Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.Translational pediatrics · 2026Article
- Exploration of common genomic signatures of systemic juvenile idiopathic arthritis and Kawasaki disease.Clinical rheumatology · 2025Article
- Article
- Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.JCI insight · 2023Article
- The reduced SCFA-producing gut microbes are involved in the inflammatory activation in Kawasaki disease.Frontiers in immunology · 2023Article
- Identification of key signaling pathways and hub genes related to immune infiltration in Kawasaki disease with resistance to intravenous immunoglobulin based on weighted gene co-expression network analysis.Frontiers in molecular biosciences · 2023Article
- Identifying differentially expressed genes and miRNAs in Kawasaki disease by bioinformatics analysis.Scientific reports · 2022Article
- Advances in understanding Kawasaki disease-related immuno-inflammatory response and vascular endothelial dysfunction.Pediatric investigation · 2022Review
- Expression of Eosinophilic Subtype Markers in Patients with Kawasaki Disease.International journal of molecular sciences · 2022Article
- TREM2 macrophages induced by human lipids drive inflammation in acne lesions.Science immunology · 2022Article
- Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis.Cell death discovery · 2022Article
- MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients.Frontiers in immunology · 2022Article
- Comprehensive Analysis of Expression and Prognostic Value of MS4As in Glioma.Frontiers in genetics · 2022Article
- KDmarkers: A biomarker database for investigating epigenetic methylation and gene expression levels in Kawasaki disease.Computational and structural biotechnology journal · 2022Article
- CD36 is Associated With the Development of Coronary Artery Lesions in Patients With Kawasaki Disease.Frontiers in immunology · 2022Article
- Toll-like receptor 4 methylation grade is linked to depressive symptom severity.Translational psychiatry · 2021Article
- Epigenetics in Kawasaki Disease.Frontiers in pediatrics · 2021Review
- Kawasaki Disease and Allergic Diseases.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kawasaki disease (KD) is a common systemic vasculitides in children younger than 5 years of age. Activated macrophages are key drivers of vascular inflammation in KD. The aim of this study was to examine differences in M1 and M2 macrophage marker expression in patients with KD. Blood samples were obtained from 18 healthy controls and 18 patients with KD at 24 h prior and 21 days after to intravenous immunoglobulin therapy. GeneChip Human Transcriptome Array 2.0 and Illumina HumanMethylation450 BeadChip were used to examined the mRNA expression and corresponding CpG site methylation ratios of 10 M1 surface markers and 15 M2 surface markers. Of the markers examined 2 M1 markers (TLR2, IL2RA) and 8 M2 markers (ARG1, CCR2, TLR1, TLR8, TLR5, MS4A6A, CD36, and MS4A4A) showed increased mRNA expression in the acute phase of KD which decreased after IVIG therapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.